The Phase I trial will assess the safety and tolerability of E10030, an anti-PDGF aptamer, in combination with an anti-VEGF agent. E10030 is the first of three compounds that Ophthotech is developing to treat AMD. This trial will enroll up to a maximum of 36 patients.
Samir Patel, president and CEO of Ophthotech, said: “We believe E10030 holds great promise for enhancing the visual outcome for patients with AMD.”